返回 
加入收藏
研发费用加计扣除政策对医药制造业研发投入与盈利能力的影响
x
请在关注微信后，向客服人员索取文件
| 篇名： | 研发费用加计扣除政策对医药制造业研发投入与盈利能力的影响 |
| TITLE： | Effects of R&D Expenses Additional Deduction Policy on R&D Investment and Profitability of Pharmaceutical Manufacturing Industry |
| 摘要： | 目的：研究研发费用加计扣除政策对医药制造业研发投入与盈利能力的影响，为提升医药制造业研发投入水平及盈利能力提供参考。方法：基于2012－2019年A股上市医药企业数据，采用断点回归方法、描述性方法，实证分析研发费用加计扣除对医药制造业研发投入与盈利能力的政策效应。结果：研发投入与主营业务利润率均在政策断点处发生显著性“跳跃”，研发费用加计扣除政策对医药制造业研发投入与盈利能力的政策效应系数分别为0.310、－1.197（P＜0.001）；对东部地区企业研发投入的政策效应系数为0.413（P＜0.001），对中、西部地区企业影响不显著；对大型、中小型医药制造业研发投入的政策效应系数分别为0.502、0.264（P均小于0.001）。结论：总体来看，研发费用加计扣除政策对医药制造业研发投入具有正向激励作用，而对其盈利能力不具有正向激励作用（盈利能力受其他因素影响）；该政策对医药制造业研发投入的激励效果具有区域性差异；对大型医药制造业研发投入的激励效果优于中小型企业。建议细化完善研发费用加计扣除政策，合理提高医药制造业利润空间，针对不同区域调整政策给予对象，并侧重引导政策向中小型企业倾斜，以提高我国医药制造业研发投入和盈利能力。 |
| ABSTRACT： | OBJECTIVE：To stu dy the effects of R&D expense additional deduction policy on R&D investment and profitability of pharmaceutical manufacturing industry ， and to provide reference for improving R&D investment and profitability of pharmaceutical manufacturing industry. METHODS ：Based on the data of Chinese pharmaceutical listed enterprises during 2012-2019，regression discontinuity design and descriptive method were adopted to analyze the effect of R&D expenses additional deduction policy on R&D investment and profitability of pharmaceutical manufacturing industry. RESULTS ：Both R&D investment and the main business profit margin had significant “jump”at the policy cutoff point ，and the policy effect coefficient of the R&D expenses additional deduction policy on R&D investment and profitability of the pharmaceutical manufacturing industry were 0.310 and －1.197 respectively（P＜0.001）. The policy effect coefficient of the policy on R&D investment in the eastern region was 0.413（P＜0.001），while the effect on central and western regions were not significant ；the policy effect coefficient of the policy on R&D investment of large-scale and small- and medium-scale pharmaceutical manufacturing industry were 0.502 and 0.264 respectively（P＜0.001）. CONCLUSIONS ：On the whole ，R&D expenses additional deduction policy has a positive incentive impact on R&D investment of pharmaceutical manufacturing industry ，but does not have a positive incentive impact on the profitability which is greatly affected by other factors. The policy has regional differences in the incentive impact on R&D investment of pharmaceutical manufacturing industry ；the incentive impact of the policy on the R&D investment of large-scale pharmaceutical manufacturing industry is better than that of small-and medium-scale one. It is recommended to improve the R&D expenses additional deduction policy ，reasonably increase the profit margin of the pharmaceutical manufacturing industry ，adjust the policy for different regions and focus on guiding policies to favor small- and medium-scale pharmaceutical manufacturing industry，so as to improve the R&D investment and profitability of pharmaceutical manufacturing industry. |
| 期刊： | 2021年第32卷第11期 |
| 作者： | 李缘，孟光兴 |
| AUTHORS： | LI Yuan，MENG Guangxing |
| 关键字： | 研发费用加计扣除；医药制造业；研发投入；盈利能力；断点回归 |
| KEYWORDS： | R&D expenses additional deduction ；Pharmaceutical manufacturing industry ；R&D investment ；Profitability； |
| 阅读数： | 610 次 |
| 本月下载数： | 4 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
